Cystic Fibrosis Antisense Oligonucleotide Therapy Gets Funding Boost

The biotech company SpliSense received an investment of up to $8.4 million from the Cystic Fibrosis Foundation to develop an antisense oligonucleotide (ASO) therapy for people with cystic fibrosis who have splicing mutations.